---
title: "Silver breaks above $70, Novo Nordisk surges 9% on obesity pill approval. Wall Street rises, S&P 500 at 6,900, with 4.3% US GDP growth in Q3. Fed easing expectations decrease to 15%."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270647866.md"
description: "Silver prices exceeded $70, and Novo Nordisk's stock surged 9% following the approval of its obesity pill. Wall Street experienced gains with the S&P 500 reaching 6,900, driven by a 4.3% growth in US GDP for Q3. Expectations for Federal Reserve easing decreased, with only a 15% chance of a rate cut in January."
datetime: "2025-12-23T18:22:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270647866.md)
  - [en](https://longbridge.com/en/news/270647866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270647866.md)
generator: "portal-rs"
---

# Silver breaks above $70, Novo Nordisk surges 9% on obesity pill approval. Wall Street rises, S&P 500 at 6,900, with 4.3% US GDP growth in Q3. Fed easing expectations decrease to 15%.

On Wednesday, Wall Street saw modest gains as investors anticipated a strong year-end period. By midday in New York, the S&P 500 rose to around 6,900, nearing October’s record of 6,920. The Nasdaq 100 also increased by 0.4% while the Dow Jones Industrial Average went up by 0.3%. However, small caps did not perform as well, with the Russell 2000 down by approximately 0.6%. The day was influenced by the release of better-than-expected U.S. GDP data. In the third quarter, the GDP grew at a 4.3% annualized rate, surpassing the estimated 3.3% and being the quickest growth in two years. As a result, traders adjusted their expectations for Federal Reserve easing. There is now a 15% likelihood of a 25-basis-point cut in late January, reduced from the previous day’s 20%.

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Nanexa AB (publ) (NANEXA) Licenses PharmaShell to Novo for Up to €1.165B](https://longbridge.com/en/news/300057979.md)
- [Novo Nordisk's hemophilia drug clears a key hurdle in Europe](https://longbridge.com/en/news/299356317.md)
- [Coca-Cola Hasn't Sold Much More Soda in a Decade. Its Dividend Has Gone Up Every Year Anyway.](https://longbridge.com/en/news/300177696.md)
- [Alphabet vs. Tesla: One Mag 7 Stock Is a Winner, the Other Faces Too Many Questions](https://longbridge.com/en/news/300143230.md)
- [BUZZ-ADARx Pharmaceuticals set to open higher in Nasdaq debut after upsized $446.3 million IPO](https://longbridge.com/en/news/300145098.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**